Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 19/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323240 | 0.82 | NR3C2 (0.45) | NR3C2KMT2A | |
| SCHEMBL7106525 | 0.81 | IGF1R (0.33) | NR3C2KMT2A | |
| SCHEMBL4303917 | 0.80 | NPC1 (0.53) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3921965 | 0.80 | IGF1R (0.44) | NR3C2KMT2A | |
| SCHEMBL28372044 | 0.79 | MAPK14 (0.48) | — | |
| SCHEMBL15940791 | 0.77 | NPC1 (0.39) | NR3C2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL13950725 | 0.76 | RIOK2 (0.49) | NR3C2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL331281 | 0.75 | NOS3 (0.51) | KMT2A | |
| SCHEMBL31139328 | 0.75 | BACE1 (0.34) | — | |
| SCHEMBL6181374 | 0.74 | NR3C2 (0.48) | NR3C2ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1858893-A1 | 1,3-THIAZOLE-5-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer Pharmaceuticals Corporation (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1765811-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006096338-A1 | 1,3-THIAZOLE-5-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE AG (DE) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006002383-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | NR3C2 2281/4885ALDH1A1 611/4885KMT2A 519/4885 |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | MCL1, HDAC5, HDAC6 | NR3C2 4712/4885ALDH1A1 370/4885KMT2A 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.